Target Name: CCNE1
NCBI ID: G898
Review Report on CCNE1 Target / Biomarker Content of Review Report on CCNE1 Target / Biomarker
CCNE1
Other Name(s): Cyclin E1 | CCNE1_HUMAN | Cyclin-E1 | cyclin E1 | Cyclin Es | LMW-CCNE1_(HUMAN) | G1/S-specific cyclin-E1 (isoform 1) | pCCNE1 | Cyclin Et | G1/S-specific cyclin-E1 | Cyclin E | CCNE | CCNE1 variant 1 | Cyclin E1, transcript variant 1 | lower molecular weight (LMW) fragments G1/S-specific cyclin-E1

CCNE1: A Protein Target for Drug Development

Cyclin E1 (CCNE1) is a protein that is expressed in various tissues throughout the body. It plays a critical role in cell division and growth, and is often used as a drug target or biomarker. In this article, we will discuss the biology and functions of CCNE1, and its potential as a drug target.

Biochemistry and Functions

CCNE1 is a 21-kDa protein that is expressed in a variety of tissues, including muscle, liver, and brain. It is composed of two major domains: an N-terminal alpha-helix domain and a C-terminal beta-sheet domain. The N-terminal domain contains a unique farnesylated cysteine 鈥嬧?媟esidue, which is important for its stability and localization in the membrane. The C-terminal domain contains a series of conserved repeats that are involved in the formation of a dimeric complex with the N-terminal domain.

In cell biology, CCNE1 is involved in various cellular processes, including cell division, growth, and the regulation of cell signaling pathways. It is a component of the cyclin D1 complex, which is responsible for regulating cell division by preventing the progression of the cell from G1 to S2. In addition, CCNE1 is involved in the regulation of the growth factor FGF-2 signaling pathway, which is critical for tissue growth and development.

As a drug target, CCNE1 has been identified as a potential target for a variety of drugs, including inhibitors of the tyrosine kinase pathway and the mitochondrial complex. In addition, CCNE1 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drugs that Interact with CCNE1

Several drugs have been shown to interact with CCNE1 and to affect its function. One of the most well-known drugs is the tyrosine kinase inhibitor gefitinib, which is used to treat various types of cancer. Gefitinib works by inhibiting the activity of the tyrosine kinase , which is a protein that is involved in cell signaling pathways. This inhibition leads to the inhibition of cell division and the inhibition of the growth of cancer cells.

Another drug that has been shown to interact with CCNE1 is the DNA damage repair inhibitor, p53. P53 is a protein that is involved in the regulation of DNA repair and is a potential drug target for cancer. P53 has been shown to interact with CCNE1 and to affect its stability. This interaction may contribute to the inhibition of cell division that is observed with gefitinib.

In addition to gefitinib and p53, several other drugs have been shown to interact with CCNE1 and to affect its function. These drugs include inhibitors of the mitochondrial complex, which is a protein that is involved in the regulation of cell energy metabolism; and inhibitors of the farnesylated cysteine 鈥嬧?媟esidue, which is involved in the stability and localization of CCNE1 in the membrane.

Conclusion

In conclusion, CCNE1 is a protein that is involved in various cellular processes and has been shown to interact with a variety of drugs. Its function as a drug target or biomarker makes it an attractive target for the development of new therapies for a variety of diseases . Further research is needed to fully understand the role of CCNE1 in cell biology and its potential as a drug target.

Protein Name: Cyclin E1

Functions: Essential for the control of the cell cycle at the G1/S (start) transition

The "CCNE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A